DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,008 filers reported holding DANAHER CORPORATION in Q1 2022. The put-call ratio across all filers is 1.38 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,762 | -13.4% | 1,704 | -16.2% | 0.11% | -5.2% |
| Q2 2023 | $488,160 | -1.5% | 2,034 | +3.5% | 0.12% | -8.7% |
| Q1 2023 | $495,511 | +9.7% | 1,966 | +15.5% | 0.13% | 0.0% |
| Q4 2022 | $451,745 | +2.2% | 1,702 | -0.5% | 0.13% | -10.6% |
| Q3 2022 | $441,934 | +6.0% | 1,711 | +3.9% | 0.14% | +8.4% |
| Q2 2022 | $417,000 | -7.7% | 1,646 | +6.7% | 0.13% | +12.0% |
| Q1 2022 | $452,000 | -28.1% | 1,542 | -19.3% | 0.12% | -27.3% |
| Q4 2021 | $629,000 | +5.2% | 1,911 | -2.6% | 0.16% | -10.6% |
| Q3 2021 | $598,000 | +7.0% | 1,963 | -5.8% | 0.18% | +11.1% |
| Q2 2021 | $559,000 | +41.9% | 2,084 | +18.9% | 0.16% | +19.1% |
| Q1 2021 | $394,000 | +18.0% | 1,752 | +16.5% | 0.14% | +15.3% |
| Q4 2020 | $334,000 | +54.6% | 1,504 | +50.0% | 0.12% | +38.8% |
| Q3 2020 | $216,000 | – | 1,003 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |